Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Takeda and Shire announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to…
Takeda Pharmaceutical completed its $62-billion acquisition of Shire, the largest-ever foreign acquisition by a Japanese company, creating a global,…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda acquired Shire for approximately $62 billion in the largest-ever foreign acquisition by a Japanese company, gaining a leading rare disease and plasma-derived therapies portfolio and transforming into a global top-10 biopharmaceutical company with over $30 billion in combined revenue.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Shire plc (this deal) | 2018 | $62.0B | 8 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2018 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals